Standard BioTools Inc (LAB) has projected its fiscal year 2026 revenue to be between $80 million and $85 million. The company, which specializes in medical devices and instruments, operates with a strong balance sheet due to low debt-to-equity and strong liquidity, despite facing profitability challenges and being in a distress zone according to the Altman Z-Score. Valuation metrics show a complex scenario, with the stock approaching oversold territory and institutional ownership at 73.85%, complemented by recent insider buying.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
LAB Forecasts Revenue Between $80 Million and $85 Million for FY
Standard BioTools Inc (LAB) has projected its fiscal year 2026 revenue to be between $80 million and $85 million. The company, which specializes in medical devices and instruments, operates with a strong balance sheet due to low debt-to-equity and strong liquidity, despite facing profitability challenges and being in a distress zone according to the Altman Z-Score. Valuation metrics show a complex scenario, with the stock approaching oversold territory and institutional ownership at 73.85%, complemented by recent insider buying.